Navigation Links
Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
Date:9/3/2013

ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 15th annual Rodman & Renshaw Healthcare Conference on Tuesday, September 10, at 11:40 a.m. EST, in Room 7.03, 7th Floor, of the Millennium Broadway Hotel in New York City. Garr will provide an overview of the company's upcoming NSI-566 cell therapy clinical trials, including ALS Phase II, ischemic stroke Phase I/II, and chronic and acute spinal cord injury Phase I. He will also provide an update on the novel neurogenic small molecule drug, NSI-189, Phase Ib clinical trial in major depressive disorder. To view the live webcast, visit Neuralstem's Investor Center at www.neuralstem.com, or: http://wsw.com/webcast/rrshq23/CUR.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 15th annual Rodman & Renshaw Healthcare Conference is being held at the Millennium Broadway Hotel in New York City, September 8-10. For more information, see: http://www.meetmax.com/sched/event_20174/~public/conference_home.html?event_id=20174

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's<
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
11. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... HAYWARD, Calif. and SHANGHAI ... Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, ... Phase 2 clinical study for its lead drug ... designed to treat drug-resistant bacteria such as MRSA ... safer and better tolerated therapeutic option than currently ...
(Date:8/31/2015)... 31, 2015 Trimb Healthcare AB ("Trimb") today ... YouMedical Group BV ("YouMedical"), a Dutch OTC company with ... sales of approximately EUR 16 million, with solid growth ... "Our ambition is to build a leading international OTC ... that goal. YouMedical gives us a stronger North European ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for ... first commercially available new FDA approved system in the last 14 years, and the ... high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Global & USA ... offering. The highly awaited US Biosimilar market ... highly awaited filigrastim biologic, Zarxio. How will the global ... The author reveals that biosimilars could save the US ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... This release is available in German . When ... light particles, so-called photons, carry sufficient energy, the electrons can be ... was explained by Einstein more than hundred years ago. Until now, ... the atom immediately after the impact of the photon. This point ...
... ... case study that provides a sustainable solution for odor and pathogen ... of beneficial microbial applications. These results are intended to address the ... who recently agreed to identify and investigate thousands of factory farms ...
... ... in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in ... , ... 24, 2010 -- Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem ...
Cached Biology Technology:Delayed time zero in photoemission 2Delayed time zero in photoemission 3Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study 2Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director &#8211; Latin America 2
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... of continental drift provides a good model for understanding terrestrial ... successfully shed light on processes up to 3 billion years ... the earth and crust formation before that point and through ... ago. This is the conclusion of Tomas Naraa of the ...
... tissue using cells derived from the amniotic fluid is ... UCL Institute of Child Health. The paper ... cells derived from the fluids which surround the fetus ... The treatment resulted in longer survival in mice affected ...
... Inc., a Los Angeles based investment banking company, today ... Alliqua, Inc.  During the term of the engagement, WestPark ... and finance, private and public equity and debt financing, ... provide introductions to investors. About Alliqua, ...
Cached Biology News:New understanding of terrestrial formation has significant and far reaching future implications 2Potential new approach to regenerating skeletal muscle tissue 2WestPark Capital, Inc. Engaged By Alliqua, Inc. 2